Compare MYGN & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | ECX |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United Kingdom |
| Employees | N/A | 1432 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 451.9M |
| IPO Year | 1996 | N/A |
| Metric | MYGN | ECX |
|---|---|---|
| Price | $5.67 | $0.99 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $7.64 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 792.6K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $6.86 | $819.14 |
| Revenue Next Year | $5.45 | $32.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.53 | $0.88 |
| 52 Week High | $8.59 | $2.70 |
| Indicator | MYGN | ECX |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 35.98 |
| Support Level | $5.57 | $0.90 |
| Resistance Level | $6.34 | $1.30 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 3.51 | 0.91 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the Peoples Republic of China. The companies core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.